Cargando…
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
BACKGROUND: BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers h...
Autores principales: | Cruz, C, Castroviejo-Bermejo, M, Gutiérrez-Enríquez, S, Llop-Guevara, A, Ibrahim, Y H, Gris-Oliver, A, Bonache, S, Morancho, B, Bruna, A, Rueda, O M, Lai, Z, Polanska, U M, Jones, G N, Kristel, P, de Bustos, L, Guzman, M, Rodríguez, O, Grueso, J, Montalban, G, Caratú, G, Mancuso, F, Fasani, R, Jiménez, J, Howat, W J, Dougherty, B, Vivancos, A, Nuciforo, P, Serres-Créixams, X, Rubio, I T, Oaknin, A, Cadogan, E, Barrett, J C, Caldas, C, Baselga, J, Saura, C, Cortés, J, Arribas, J, Jonkers, J, Díez, O, O’Connor, M J, Balmaña, J, Serra, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961353/ https://www.ncbi.nlm.nih.gov/pubmed/29635390 http://dx.doi.org/10.1093/annonc/mdy099 |
Ejemplares similares
-
A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019) -
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
por: Castroviejo‐Bermejo, Marta, et al.
Publicado: (2018) -
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017) -
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
por: Martinez-Marti, A, et al.
Publicado: (2017) -
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
por: Vilar, E, et al.
Publicado: (2008)